Estradiol

Is estradiol safe for menopause?

For most healthy women who start it under 60 or within 10 years of their last period, yes: the benefits for hot flushes, sleep and vaginal symptoms usually outweigh risks that are small in absolute terms. Estradiol is the estrogen in most menopausal hormone therapy (HRT), sold as tablets, patches, gels, vaginal tablets and rings. This page covers menopause use only, not contraceptive pills.

The risks are real but depend heavily on who takes it and how. Blood clots, stroke and breast cancer rise with age, with years of use and when a progestogen is added. Women with a uterus need a progestogen to protect the womb lining. We score estradiol 77, nine points above testosterone (68), mainly because it has no misuse potential; its weak points are long-term cancer and clot risks.

What happened to the boxed warning?

For more than 20 years, US estrogen labels carried a boxed warningBoxed warningThe strongest safety warning the US FDA puts on a medicine's label, printed inside a black border at the top.More in the glossary on heart disease, stroke, breast cancer and probable dementia, based on the Women's Health Initiative (WHI) trials. Those trials mostly enrolled women in their 60s and 70s, years after menopause.

On 10 November 2025 the FDA announced it would remove heart disease, breast cancer and probable dementia from the box, keeping only endometrial cancer for products containing estrogen alone. It also asked labels to suggest starting systemic therapy before 60 or within 10 years of menopause, and asked makers to drop the advice to use hormones for the shortest possible time.

The change is rolling out product by product. Updated estradiol gel labels (Divigel and a generic) show the removal dated February 2026, and the Estring vaginal ring label of April 2026 has no box at all. But Climara, Vivelle-Dot, Vagifem and many generic tablet labels we checked still carried the full warning in October 2026. The underlying risks did not change; they moved out of the box into the warnings section.

How big are the risks?

From the current labels, in women aged 50 to 59 taking estrogen alone (WHI):

Event per 10,000 women a year	Estrogen alone	Placebo
Clot in the lungs	10	6
Leg clot (DVT)	13	8
Stroke	16	17
Invasive breast cancer	24	29

Across all ages (50 to 79), strokes were more common on estrogen (45 vs 34). With a progestogen added, the WHI found more invasive breast cancer: 41 vs 33 cases per 10,000 women a year.

Longer observational data are less reassuring on breast cancer than the WHI alone. The MHRA, using a 2019 meta-analysis of 108,647 cases, estimates that 5 years of HRT from menopause adds about 5 breast cancers per 1,000 women by age 69 for estrogen alone, 14 for monthly progestogen and 20 for daily progestogen. Ten years roughly doubles that. Some excess risk lasts more than 10 years after stopping.

Other label warnings: endometrial cancer 2 to 12 times more common with estrogen alone in women with a uterus, gallbladder disease needing surgery 2 to 4 times more often, high triglycerides, and rarely, eye clots.

Label doses by form

• Tablets: usually 1 to 2 mg a day, adjusted to control symptoms.
• Patch (Minivelle): starts at 0.0375 mg a day, changed twice a week.
• Gel (Divigel and generics): 0.25 to 1.25 g a day on the upper thigh, alternating sides.
• Vaginal tablet (Vagifem 10 mcg): one daily for 2 weeks, then twice a week.
• Vaginal ring (Estring): releases about 7.5 mcg a day and is replaced every 90 days.

Low-dose vaginal products mainly treat dryness and pain with sex, and the MHRA found no effect on breast cancer risk from them.

Interactions and overdose

Estrogens are processed by the liver enzyme CYP3A4CYP450 enzymesA family of liver enzymes that break down many medicines. When another drug or supplement speeds them up or slows them down, drug levels change.More in the glossary. St John's wort, rifampin, carbamazepine and phenobarbital can lower estradiol levels and change bleeding patterns; clarithromycin, ketoconazole, ritonavir and grapefruit juice can raise them. Women on levothyroxine may need a higher dose, because estrogen raises thyroid-binding protein. Herbal menopause remedies such as black cohosh have safety questions of their own.

Overdose is not dangerous in the usual sense: the label lists nausea, vomiting, breast tenderness, drowsiness and withdrawal bleeding.

Who should be careful

The labels rule out estradiol after breast cancer or an estrogen-dependent cancer, after a blood clot, stroke or heart attack, with liver disease, a clotting disorder or unexplained vaginal bleeding. Talk to your doctor or pharmacist if you have migraines, high triglycerides, gallbladder disease or are over 60, and about whether tablets, patches or vaginal products suit you. Any bleeding after menopause needs checking. Stop and get urgent help for chest pain, sudden breathlessness, leg swelling, vision loss or signs of stroke, and stop estradiol 4 to 6 weeks before major surgery if your surgeon advises it.

How we scored it

Dependence (95), overdose marginOverdose marginHow far a normal dose is from a harmful one. A wide margin means an accidental extra dose is unlikely to cause serious harm.More in the glossary (92) and track record (92) are strong. Interactions (78) lose points for CYP3A4CYP450 enzymesA family of liver enzymes that break down many medicines. When another drug or supplement speeds them up or slows them down, drug levels change.More in the glossary effects. Regulatory warnings (50) reflect a boxed warningBoxed warningThe strongest safety warning the US FDA puts on a medicine's label, printed inside a black border at the top.More in the glossary that is narrowing but not gone. Serious side effects (60) carry the most weight: clots, stroke and breast cancer are uncommon in younger women but real. A lower score does not mean you should stop; talk to your prescriber first.